Alterity Therapeutics Announces Notification of Unquoted Securities

Alterity Therapeutics Limited filed a Form 6-K on April 20, 2026, to provide a notification regarding unquoted securities. The filing serves as a formal update to the Securities and Exchange Commission (SEC) concerning changes or issuances in the company\'s unlisted equity instruments. This report is incorporated by reference into several of the company’s existing Registration Statements, including those on Form S-8 and Form F-3, which typically relate to employee stock incentive plans and shelf registrations for future capital raises. Julian Babarczy, Chairman of Alterity Therapeutics, signed the document. While the specific details of the unquoted securities (such as the exact number of options or warrants issued or cancelled) are referenced in Exhibit 99.1, the primary purpose of this filing is to maintain regulatory compliance regarding the company\'s capital structure. No clinical trial data or updates to the company\'s drug development pipeline were included in this specific administrative filing.